search icon
pyxs-img

Pyxis Oncology Inc, Common Stock

PYXS

NSQ

$1.25

+$0.05

(4.17%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$74.34M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
304.69K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.15
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.83 L
$5.39 H
$1.25

About Pyxis Oncology Inc, Common Stock

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FramePYXSSectorS&P500
1-Week Return4.17%0.71%0.79%
1-Month Return20.19%-5.6%6.04%
3-Month Return5.04%-11.72%-1.11%
6-Month Return-37.81%-10.81%-2.39%
1-Year Return-67.11%-7.12%11.69%
3-Year Return-49.39%-0.57%42.29%
5-Year Return-90.53%27.64%93.12%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue----16.15M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue444.00K1.25M1.84M2.00M475.00K[{"date":"2020-12-31","value":22.2,"profit":true},{"date":"2021-12-31","value":62.55,"profit":true},{"date":"2022-12-31","value":91.8,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":23.75,"profit":true}]
Gross Profit(444.00K)(1.25M)(1.84M)(2.00M)15.67M[{"date":"2020-12-31","value":-2.83,"profit":false},{"date":"2021-12-31","value":-7.98,"profit":false},{"date":"2022-12-31","value":-11.72,"profit":false},{"date":"2023-12-31","value":-12.76,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(Infinity%)97.06%[{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses12.89M69.72M123.48M82.20M105.13M[{"date":"2020-12-31","value":10.44,"profit":true},{"date":"2021-12-31","value":56.46,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":66.57,"profit":true},{"date":"2024-12-31","value":85.14,"profit":true}]
Operating Income(12.89M)(69.72M)(123.48M)(82.20M)(89.46M)[{"date":"2020-12-31","value":-1289400000,"profit":false},{"date":"2021-12-31","value":-6971700000,"profit":false},{"date":"2022-12-31","value":-12348100000,"profit":false},{"date":"2023-12-31","value":-8219600000,"profit":false},{"date":"2024-12-31","value":-8946000000,"profit":false}]
Total Non-Operating Income/Expense132.00K(6.24M)5.53M15.31M17.00M[{"date":"2020-12-31","value":0.78,"profit":true},{"date":"2021-12-31","value":-36.67,"profit":false},{"date":"2022-12-31","value":32.51,"profit":true},{"date":"2023-12-31","value":90.06,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(12.83M)(75.97M)(120.72M)(73.79M)(79.50M)[{"date":"2020-12-31","value":-1282800000,"profit":false},{"date":"2021-12-31","value":-7597500000,"profit":false},{"date":"2022-12-31","value":-12071700000,"profit":false},{"date":"2023-12-31","value":-7379000000,"profit":false},{"date":"2024-12-31","value":-7949500000,"profit":false}]
Income Taxes(66.00K)5.56M(2.76M)1.78M(2.16M)[{"date":"2020-12-31","value":-1.19,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-49.7,"profit":false},{"date":"2023-12-31","value":31.94,"profit":true},{"date":"2024-12-31","value":-38.91,"profit":false}]
Income After Taxes(12.76M)(81.54M)(117.95M)(75.57M)(77.33M)[{"date":"2020-12-31","value":-1276200000,"profit":false},{"date":"2021-12-31","value":-8153600000,"profit":false},{"date":"2022-12-31","value":-11795300000,"profit":false},{"date":"2023-12-31","value":-7556600000,"profit":false},{"date":"2024-12-31","value":-7733100000,"profit":false}]
Income From Continuous Operations(12.83M)(75.97M)(120.72M)(94.29M)(77.33M)[{"date":"2020-12-31","value":-1282800000,"profit":false},{"date":"2021-12-31","value":-7597500000,"profit":false},{"date":"2022-12-31","value":-12071700000,"profit":false},{"date":"2023-12-31","value":-9429400000,"profit":false},{"date":"2024-12-31","value":-7733100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(12.76M)(81.54M)(117.95M)(73.79M)(77.33M)[{"date":"2020-12-31","value":-1276200000,"profit":false},{"date":"2021-12-31","value":-8153600000,"profit":false},{"date":"2022-12-31","value":-11795300000,"profit":false},{"date":"2023-12-31","value":-7379000000,"profit":false},{"date":"2024-12-31","value":-7733100000,"profit":false}]
EPS (Diluted)(18.67)(27.89)(3.62)(1.85)(0.96)[{"date":"2020-12-31","value":-1866.82,"profit":false},{"date":"2021-12-31","value":-2789.09,"profit":false},{"date":"2022-12-31","value":-362,"profit":false},{"date":"2023-12-31","value":-185,"profit":false},{"date":"2024-12-31","value":-96.22,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

PYXS
Cash Ratio 7.31
Current Ratio 7.75

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

PYXS
ROA (LTM) -29.19%
ROE (LTM) -66.31%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

PYXS
Debt Ratio Lower is generally better. Negative is bad. 0.24
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.76

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

PYXS
Trailing PE NM
Forward PE NM
P/S (TTM) 4.11
P/B 0.75
Price/FCF NM
EV/R 5.08
EV/Ebitda 1.09

FAQs

What is Pyxis Oncology Inc share price today?

Pyxis Oncology Inc (PYXS) share price today is $1.25

Can Indians buy Pyxis Oncology Inc shares?

Yes, Indians can buy shares of Pyxis Oncology Inc (PYXS) on Vested. To buy Pyxis Oncology Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PYXS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Pyxis Oncology Inc be purchased?

Yes, you can purchase fractional shares of Pyxis Oncology Inc (PYXS) via the Vested app. You can start investing in Pyxis Oncology Inc (PYXS) with a minimum investment of $1.

How to invest in Pyxis Oncology Inc shares from India?

You can invest in shares of Pyxis Oncology Inc (PYXS) via Vested in three simple steps:

  • Click on Sign Up or Invest in PYXS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Pyxis Oncology Inc shares
What is Pyxis Oncology Inc 52-week high and low stock price?

The 52-week high price of Pyxis Oncology Inc (PYXS) is $5.39. The 52-week low price of Pyxis Oncology Inc (PYXS) is $0.83.

What is Pyxis Oncology Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Pyxis Oncology Inc (PYXS) is 0.75

What is the Market Cap of Pyxis Oncology Inc?

The market capitalization of Pyxis Oncology Inc (PYXS) is $74.34M

What is Pyxis Oncology Inc’s stock symbol?

The stock symbol (or ticker) of Pyxis Oncology Inc is PYXS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top